

24th August, 2011

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001.

AJANTA HOUSE
Charkop, Kandivli (W),
MUMBAI - 400 067, INDIA
Tel. : (+91)22-6606 1000
Fax : (+91)22-6606 1200 / 300
E-mail : info@ajantapharma.com
Website : www.ajantapharma.com

Dear Sir/Madam,


Re.: Approval received from MHRA of UK for our manufacturing facility at Paithan

This is to inform the Stock Exchange that the company has received approval from Medicines & Healthcare products regulatory Agency (MHRA) of United Kingdom (UK) for its formulation manufacturing facility situated at Paithan, Aurangabad, India.

Please find enclosed Press Release for the same and acknowledge the receipt.

Thanking you,

Yours faithfully,
For **AJANTA PHARMA LIMITED**



NIKHIL BHATT
G.M. - Legal &
Company Secretary

c.c. : National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051.

Encl.: a/a.

COMPANY CONTACT:

Ajanta House,
Charkop, Kandivli (West),
Mumbai – 400 067
+91 22 66061000
www.ajantapharma.com

INVESTOR CONTACTS:

Nikhil Bhatt
Company Secretary
+91 22 66061204
nikhilb@ajantapharma.com

Press Release

Ajanta Pharma gets UK MHRA Approval

Mumbai – (August 24, 2011) – Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company, has received approval from Medicines & Healthcare products Regulatory Agency (MHRA) of United Kingdom (UK) for its formulation manufacturing facility at Paithan, Aurangabad, India. Mr. Yogesh Agrawal, Managing Director described the facility approval as “significant milestone, paving the way for entry to the European Union market”.

Ajanta Pharma’s Paithan manufacturing facility is already approved by US FDA and has by now obtained the approval for one ANDA. Another ANDA is under approval and number of other ANDA’s are in process of filing. Besides USA and UK, world’s two most stringent regulatory approvals, Ajanta’s Paithan facility also holds the WHO Pre-qualification approval from WHO Geneva.

Commenting on the development, Mr. Yogesh Agrawal, Managing Director said. “We continue to build expertise in the quality standards and approvals from the most stringent regulatory authorities like USA, UK and WHO Pre-qualification are testimony to our commitment towards quality. The foundation being laid down now shall assure sustained growth for the company in years to come”

About Ajanta pharma

Ajanta Pharma is a specialty branded fully integrated pharmaceutical formulation company, having leading brands in therapeutic segments of Ophthalmology, Dermatology and Cardiology. Many of company’s products are first of its kind and are leading in their sub therapeutic segments. Company exports its products to more than 25 countries and established strong brand equity in these markets.

Ajanta Pharma has its State of the Art R&D centre at Kandivali Mumbai, with more than 200 scientists working for formulation development. Company has world class manufacturing facilities - 4 located in India and 1 at Mauritius. For the year ending March 2011, company had the consolidated sales of Rs.510crs. (USD 114million) and has been consistently posting healthy growth in sales and profitability for last decade.

